Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

BIO-CAT Publishes Foundational Study of Digestive Enzyme Function

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

A clinical trial designed by BIO-CAT, Inc – a biotech company specializing in enzyme development – studied the use of enzymes to improve digestion in an in vitro model of aging. The results showed that a multi-component supplemental enzyme blend (microbial proteases, lipase, amylase, and glucoamylase) effectively released nutrients from a balanced meal better than control conditions, which solely relied upon endogenous enzymes similar to those already present in the human digestive system. Particularly impressive was the enhanced digestion during the acidic gastric phase, further confirming that the microbial enzymes are naturally acid-tolerant without encapsulation.

The peer-reviewed manuscript describing these results is now published in the food science journal, Food Chemistry.

The BIO-CAT R&D team chose the INFOGEST model to adapt for the study of supplemental digestive enzymes. First described in 2014, updated in 2019, and cited over 1500 times since, the INFOGEST simulation of human gastrointestinal digestion was developed by the International Network on Food Digestion with over 200 scientists from 32 countries. The INFOGEST protocol models each of salivary, gastric, and intestinal digestion with specific simulated digestion fluids, pH conditions, and enzymes to reflect human digestive physiology.

In a final series of experiments, the BIO-CAT team modified the INFOGEST protocol to model the decline in digestive function that accompanies each of advancing age and antacid use. Under both models of handicapped gastric conditions, the multi-enzyme blend was able to restore and improve macronutrient digestion and nutrient release. Additionally, BIO-CAT is now able to offer tailored INFOGEST testing for customers and partners.

The BIO-CAT publication comes on the heels of another exciting announcement from BIO-CAT. In January, the company initiated a clinical trial of the same multi-enzyme blend specifically in older adults aged 50-70 who may naturally experience changes in digestion. Study outcomes include changes nutrient absorption, gastrointestinal symptoms, and bowel function between the enzyme blend and placebo.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine